Clinical trials: completed, sponsored by AstraZeneca
Paroxysmal Nocturnal Hemoglobinuria
A Real-world, Multi-center, Prospective, Observational Study for PNH in China
As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of…
- Trial name
- ReWoPNH (NCT06154512)
- Where
- 40 sites in China
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Biliary Tract Cancer
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
To investigate onset of adverse drug reactions in patients with curatively unresectable biliary tract cancer who receive IMFINZI in combination with gemcitabine hydrochloride and cisplatin under actual use in the post-marketing…
- Trial name
- NCT05835778
- Where
- 24 sites in Japan
- Volunteers
- 236 people
- Sponsor
- AstraZeneca
Endocrinology, Diabetes, Type II
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable…
- Conditions
- Endocrinology, Diabetes, Type II, Obesity
- Trial name
- ARAY (NCT06851858)
- Testing
- AZD6234
- Where
- 18 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dyslipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density…
- Trial name
- NCT05384262
- Testing
- AZD0780, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved…
- Trial name
- NCT06502366
- Testing
- BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg
- Where
- 128 sites in United States, China and 4 more
- Volunteers
- 424 people
- Sponsor
- AstraZeneca
Moderate-to-Severe Asthma
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
This is a Prospective, Observational, Multicentre Study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China. Sponsor by Astrazeneca Investment(China) Co., LTD.
- Trial name
- PRESENT (NCT06422663)
- Where
- 31 sites in China
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Lung Cancer, Breast Cancer
Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer
A multinational observational study to evaluate the current pathology practices and the utilization of computational pathology plus artificial intelligence algorithms in patients with suspected lung and breast cancer.
- Trial name
- CASCADE (NCT06827132)
- Where
- 2 sites in Brazil, Kenya
- Volunteers
- 603 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to…
- Trial name
- STEP (NCT06465485)
- Testing
- Benralizumab
- Where
- 74 sites in China
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL).
- Trial name
- ASSURE (NCT04008706)
- Testing
- Acalabrutinib
- Where
- 108 sites in United States, Australia and 15 more
- Volunteers
- 552 people
- Sponsor
- AstraZeneca
COVID-19, SARS-CoV-2 Infection
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
- Trial name
- ARTEMIS-C (NCT06147063)
- Testing
- AZD9838, Licensed SARS-CoV-2 mRNA vaccine, AZD6563
- Where
- 5 sites in United States
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients
Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)
Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan
- Conditions
- Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients, Routine Therapy Before and After the Diagnosis of CKD
- Trial name
- D1843R00359 (NCT06744335)
- Where
- 28 sites in Kazakhstan
- Volunteers
- 1,283 people
- Sponsor
- AstraZeneca
Asthma
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years…
- Trial name
- MITCHELL (NCT06644924)
- Testing
- Intervention: AS MDI, Intervention: Ventolin Evohaler
- Where
- 22 sites in United States
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Asthma
Tezepelumab PRO Study
This study assesses the impact of tezepelumab treatment not only on asthma control but also on cough specific Health-Related Quality of Life (HRQoL). Asthma control can be evaluated using Asthma Control Questionnaire (ACQ).
- Trial name
- TezepelumabPRO (NCT05922891)
- Where
- 29 sites in Japan
- Volunteers
- 92 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending doses of AZD0292 administered via intravenous (IV) infusion in healthy Japanese participants.
- Trial name
- NCT07222254
- Testing
- AZD0292
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atypical Hemolytic Uremic Syndrome
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases per million population per year.
- Trial name
- REACH (NCT07218536)
- Where
- 6 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Resistant Hypertension
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs.
- Trial name
- Bax24 (NCT06168409)
- Testing
- Baxdrostat
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults
The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.
- Trial name
- NCT07513571
- Testing
- AZD4954, Laroprovstat
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants
The purpose of this study is to assess the effect of capivasertib on the pharmacokinetics of oral dextromethorphan in healthy participants.
- Trial name
- NCT07241065
- Testing
- Dextromethorphan, Capivasertib
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Liver Fibrosis, Hepatic Cirrhosis
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.
- Trial name
- PECHORA (NCT07069725)
- Testing
- AZD2389, PET scan and radioligand
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- AstraZeneca